Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Femara® (letrozole tablets)
- www.femarainfo.com
(For Non U.S. Health Care Professionals Only)
FEMARA CONTACT
Megan Humphrey
Novartis Oncology Global Public Relations
office +1 862 778 6724
Megan.Humphrey@novartis.com
Gloria Vanderham
Novartis Oncology Global Public Relations
office +1 862 778 4268
Gloria.Vanderham@novartis.com
Femara®(letrozole tablets) is indicated for the treatment of:
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
- Extended adjuvant treatment of hormone dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for five years.
- First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
- Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with antiestrogens.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
Femara Press Releases
10-Dec-2009
19-Aug-2009
Femara Additional Materials
-
4-Jun-2010
Femara Fact Sheet -
8-Dec-2009
BIG 1-98 Backgrounder -
8-Dec-2009
BIG 1-98 Trial Design -
8-Dec-2009
Breast Cancer Fact Sheet -
8-Dec-2009
Breast Cancer and Distant Recurrence Fact Sheet -
8-Dec-2009
Aromatase Inhibitor Fact Sheet
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.